InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (6 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
6
T+90 hit rate
17%
T+90 mean return
+1.8%
Across 6 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by BURWIG SUSAN E, Exec. VP, Operations. Insider active across 1 company, notably Medpace Holdings, Inc.. Aggregated, 15 filings have been recorded. Split: 0 buy · 6 sells. Total volume traded: €18.6m. History available since 14 June 2021. The latest transaction was filed on 18 March 2026 (Levée d'options). Regulator: SEC (Form 4). All data is openly available.
Declarations15 total
12,000 shares@ US$166.736.4% of flowCommon StockSEC:0001677418-26-000004:0
10,000 shares@ US$107.932.6% of flowCommon StockSEC:0001677418-25-000018:0
2,000 shares@ US$605.010.0065% mcap5.1% of flowCommon StockSEC:0001677418-25-000010:0
10,000 shares@ US$107.932.6% of flowCommon StockSEC:0001677418-25-000008:0
10,000 shares@ US$107.93Common StockSEC:0001677418-25-000003:0
7,500 shares@ US$450.148.2% of flowCommon StockSEC:0001668397-25-000099:0
7,500 shares@ US$32.050.6% of flowCommon StockSEC:0001668397-24-000170:0
50,000 shares@ US$90.6511.6% of flowCommon StockSEC:0001668397-24-000153:0
7,681 shares@ US$401.208.0% of flowCommon StockSEC:0001668397-24-000123:0
102 shares@ US$403.000.1% of flowCommon StockSEC:0001668397-24-000061:0
10,391 shares@ US$304.158.2% of flowCommon StockSEC:0000892251-23-000201:0
7,500 shares@ US$32.050.6% of flowCommon StockSEC:0000892251-23-000165:0
12,400 shares@ US$28.320.0019% mcap1.5% of flowCommon StockSEC:0001567619-22-005628:0
55,037 shares@ US$192.160.056% mcap43.5% of flowCommon StockSEC:0001567619-21-016795:0
7,400 shares@ US$23.000.0009% mcap0.7% of flowCommon StockSEC:0001567619-21-012190:0
15 of 15 declarations
About BURWIG SUSAN E
Susan E. Burwig is the Executive Vice President of Operations at Medpace Holdings, Inc. In this role, she oversees the company's operations, ensuring efficiency and quality of services. Her expertise in the clinical trials sector is essential in optimizing operational processes. With a strong management background, she contributes to strategic decision-making.
